GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Institutional Ownership

UPB (Upstream Bio) Institutional Ownership : 74.70% (As of Mar. 14, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Upstream Bio's institutional ownership is 74.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Upstream Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Upstream Bio's Float Percentage Of Total Shares Outstanding is 0.00%.


Upstream Bio Institutional Ownership Historical Data

The historical data trend for Upstream Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Institutional Ownership Chart

Upstream Bio Historical Data

The historical data trend for Upstream Bio can be seen below:

2024-10-31 2024-11-30 2024-12-31 2025-01-31
Institutional Ownership 10.69 11.87 21.84 21.97

Upstream Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Upstream Bio Business Description

Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.